Ypsomed announced plans to expand its offerings of digital health solutions for chronic disease therapy together with S3 Connected Health. Dublin, Ireland-based S3 Connected Health specializes as a digital health partner for life science companies. This partnership allows Ypsomed’s biopharma customers to quickly launch therapy-specific digital patient solutions. It enables therapy management support for acute […]
Insulet makes progress on integrating Omnipod 5 with Abbott FreeStyle Libre 2
Insulet (Nasdaq:PODD) today announced a duo of updates related to its Omnipod 5 system that includes a significant integration development. Acton, Massachusetts-based Insulet plans to discuss a range of developments related to its product line in the coming days at the American Diabetes Association (ADA) 83rd Scientific Sessions in San Diego. Presentations include real-world evidence […]
France expands reimbursement for Abbott FreeStyle Libre 2 to all basal insulin users
Abbott (NYSE:ABT) announced today that the French health authority approved the expansion of reimbursement coverage for the FreeStyle Libre 2. FreeStyle Libre 2 previously only had coverage for people with type 1 and type 2 diabetes who require intensive insulin therapy. France’s expansion covers the continuous glucose monitor (CGM) for all people who use basal […]
Real-world data supports Bigfoot Biomedical diabetes management platform
Bigfoot Biomedical today announced study data demonstrating the potential of its Bigfoot Unity system for diabetes management. The FDA-cleared Bigfoot Unity platform aims to simplify continuous glucose monitors (CGMs) and the data they produce. It features a smart insulin pen cap, which takes data from a CGM and informs the patient exactly how much insulin […]
Insulet makes Omnipod 5 automated insulin delivery system available in the UK
Insulet (Nasdaq:PODD) announced that it commercially launched its Omnipod 5 automated insulin delivery system in the United Kingdom. Acton, Massachusetts-based Insulet launched Omnipod 5 for individuals aged two years and older with type 1 diabetes. The latest-generation Omnipod 5 became the first tubeless, wearable automated insulin delivery system cleared for marketing in the U.S. in January […]
Eli Lilly, ADA and Red Sox star Adam Duvall launch insulin affordability awareness program
Eli Lilly (NYSE:LLY) and the American Diabetes Association partnered with MLB player Adam Duvall to increase insulin affordability awareness. Lilly, ADA and Duvall agreed to launch a nationwide effort to highlight affordable insulin for all living with diabetes. This effort comes on the heels of Lilly’s announcement in March that it planned to significantly cut […]
FDA approves Surmodics SurVeil drug-coated balloon
Surmodics (Nasdaq:SRDX) announced today that the FDA granted approval for its SurVeil drug-coated balloon (DCB). Eden Prairie, Minnesota-based Surmodis may now market and sell SurVeil in the U.S. for percutaneous transluminal angioplasty. Use follows appropriate vessel preparation or de novo or restenotic lesions in femoral and popliteal arteries. These arteries feature reference vessel diameters of […]
Medtronic begins U.S. shipments of MiniMed 780G, looks to next-gen CGM
Medtronic (NYSE:MDT) said it began shipping its next-generation MiniMed 780G automated insulin delivery system in the U.S. this month. Additionally, CEO Geoff Martha offered some insights into the Diabetes unit’s product pipeline during the Goldman Sachs global healthcare conference. Medtronic’s diabetes pipeline includes a next-generation continuous glucose monitor (CGM) sensor that is half the size of […]
Dexcom study shows diabetes’ impact on mental health
A new study commissioned by Dexcom (Nasdaq:DXCM) found that diabetes has significant negative effects on mental health. The study revealed that 84% of people surveyed agree that having diabetes can negatively impact mental health. It also demonstrated that nearly all participants (91%) believe technology enables a balanced lifestyle while managing diabetes. Dexcom, a maker of […]
Stevanato Group unveils on-body drug delivery device
Stevanato Group (NYSE:STVN) today unveiled Vertiva, the latest release of its patented on-body drug delivery system. Piombino Dese, Italy-based Stevanato Group designed Vertiva with the ability to switch between basal and bolus injections. It has suitability for a wide range of subcutaneous therapies. In March, Stevanato Group announced plans to bring this on-body device to […]